BioSpace News Archive

Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its fourth quarter and full-year 2022 financial results on Tuesday, February 28, 2023, after the financial markets close.

Precision Optics Corporation, Inc., a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced it has signed a production and technology license agreement with a large, global medical device company.

GI Dynamics® Inc., a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to announce the first patient in the India I-STEP clinical study has been treated at Apollo Speciality Hospital in Chennai, India in January.

Boston Scientific Corporation (NYSE: BSX) will participate in Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference on Wednesday, March 1, 2023.

MAIA Biotechnology, Inc. announced it intends to initiate its second Phase 2 go-to-market trial evaluating THIO, the world’s first telomere-targeting agent, in patients with four cancer indications.

The Canadian Medical Protective Association (CMPA) is pleased to share key findings learned from its peer-reviewed study, Diagnostic delays in sepsis: Lessons learned from a retrospective study of Canadian medico-legal claims.

PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 43rd Annual Cowen Health Care Conference in Boston.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced positive results upon completion of the U.S. clinical evaluation for the T2Biothreat™ Panel.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) (“Fusion”) today announced the acquisition from RadioMedix, Inc. (“RadioMedix”) of the investigational new drug application (“IND”) for an ongoing Phase 2 clinical trial (the “TATCIST” trial) evaluating 225Ac-PSMA I&T, a small molecule targeting prostate specific membrane antigen (“PSMA”) expressed on prostate cancers.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will report financial results for the fourth quarter and full year 2022 before market open on Monday, March 6, 2023.